ONWARD MEDICAL BV EO -12 - Asset Resilience Ratio

Latest as of June 2024: 16.01%

ONWARD MEDICAL BV EO -12 (63E) has an Asset Resilience Ratio of 16.01% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ONWARD MEDICAL BV EO -12 (63E) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€7.50 Million

≈ $8.77 Million USD Cash + Short-term Investments

Total Assets

€46.85 Million

≈ $54.78 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2022–2022)

This chart shows how ONWARD MEDICAL BV EO -12's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 63E total assets.

Liquid Assets Composition Over Time

This chart breaks down ONWARD MEDICAL BV EO -12's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of ONWARD MEDICAL BV EO -12 for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€7.50 Million	16.01%
Total Liquid Assets	€7.50 Million	16.01%

Asset Resilience Insights

Good Liquidity Position: ONWARD MEDICAL BV EO -12 maintains a healthy 16.01% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

ONWARD MEDICAL BV EO -12 Industry Peers by Asset Resilience Ratio

Compare ONWARD MEDICAL BV EO -12's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for ONWARD MEDICAL BV EO -12 (2022–2022)

The table below shows the annual Asset Resilience Ratio data for ONWARD MEDICAL BV EO -12.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	26.11%	€20.00 Million ≈ $23.38 Million	€76.59 Million ≈ $89.55 Million	--

pp = percentage points

About ONWARD MEDICAL BV EO -12

F:63E Germany Biotechnology

Market Cap

$234.10 Million

€200.24 Million EUR

Market Cap Rank

#16801 Global

#1584 in Germany

Share Price

€2.88

Change (1 day)

+1.41%

52-Week Range

€2.26 - €5.56

All Time High

€12.92